Third Security LLC Acquires 1,423,236 Shares of Intrexon Corp (XON)
Third Security LLC lifted its holdings in shares of Intrexon Corp (NYSE:XON) by 2.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 57,928,289 shares of the biotechnology company’s stock after acquiring an additional 1,423,236 shares during the quarter. Intrexon accounts for about 57.2% of Third Security LLC’s investment portfolio, making the stock its largest holding. Third Security LLC owned approximately 0.45% of Intrexon worth $667,334,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in XON. Iridian Asset Management LLC CT grew its holdings in shares of Intrexon by 22.5% during the 4th quarter. Iridian Asset Management LLC CT now owns 4,518,112 shares of the biotechnology company’s stock worth $52,049,000 after purchasing an additional 828,368 shares during the period. Frontier Capital Management Co. LLC grew its holdings in shares of Intrexon by 139.0% during the 4th quarter. Frontier Capital Management Co. LLC now owns 276,284 shares of the biotechnology company’s stock worth $3,183,000 after purchasing an additional 160,701 shares during the period. Vanguard Group Inc. grew its holdings in shares of Intrexon by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after purchasing an additional 147,517 shares during the period. Commonwealth Equity Services Inc grew its holdings in shares of Intrexon by 660.7% during the 3rd quarter. Commonwealth Equity Services Inc now owns 158,089 shares of the biotechnology company’s stock worth $3,005,000 after purchasing an additional 137,307 shares during the period. Finally, Peregrine Capital Management LLC grew its holdings in shares of Intrexon by 25.3% during the 3rd quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock worth $11,089,000 after purchasing an additional 117,605 shares during the period. Institutional investors and hedge funds own 73.31% of the company’s stock.
Intrexon Corp (NYSE:XON) opened at $13.58 on Thursday. Intrexon Corp has a twelve month low of $10.26 and a twelve month high of $26.99. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01.
A number of research firms have recently weighed in on XON. ValuEngine cut Intrexon from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Intrexon from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Bank of America lowered their target price on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Stifel Nicolaus raised their target price on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a report on Friday, November 10th. Finally, Northland Securities restated a “buy” rating and set a $21.00 target price on shares of Intrexon in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Intrexon has an average rating of “Hold” and a consensus target price of $38.50.
In other news, CEO Randal J. Kirk bought 1,000,000 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was bought at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 55.10% of the company’s stock.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.